Acellular pertussis vaccines and the role of pertactin and fimbriae

Expert Review of Vaccines

Volumn 6, Issue 1, 2007, Pages 47-56

  Poolman, Jan T ^a   Hallander, Hans O ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Acellular pertussis; Bordetella pertussis polymorphism; Vaccine efficacy; Vaccines

Indexed keywords

ALUMINUM SALT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; PEDIACEL; PEDIARIX; PENTACEL; PENTAVAC; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADSORPTION; BORDETELLA PERTUSSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FIMBRIA; GENETIC POLYMORPHISM; HEALTH PROGRAM; HUMAN; MULTIPLE CYCLE TREATMENT; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; REVIEW; TREATMENT OUTCOME; VACCINATION;

BACTERIAL OUTER MEMBRANE PROTEINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FIMBRIAE, BACTERIAL; HUMANS; PERTUSSIS VACCINE; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 33846917994     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.1.47     Document Type: Review

References (75)

1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18(2), 326-382 (2005). •• Recent review regarding pertussis epidemiology.
2. Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect. Immun. 68(4), 1934-1941 (2000).
3. Carbonetti NH, Artamonova GV, Andreasen C, Bushar N. Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect. Immun. 73(5), 2698-2703 (2005).
4. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16(20), 1901-1906 (1998).
5. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916 (1998).
6. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21(25-26), 3542-3549 (2003).
7. Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 17(19), 2366-2376 (1999).
8. Hellwig SMM, Rodriguez ME, Berbers GAM, van de Winkel JGJ, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. 188(5), 738-742 (2003).
9. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 65(10), 1367-1389 (2005).
10. Edwards KM, Decker MD. Pertussis vaccine. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, PA, USA, 471-528 (2004). •• Review of pertussis immunization.
11. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16(Suppl. 4), S90-S96 (1997).
12. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21(17-18), 2003-2014 (2003). •• Systematic review of studies assessing the efficacy and safety of DTP vaccines.
13. Olin P. The best acellular pertussis vaccines are multicomponent (commentary). Pediatr. Infect. Dis. J. 16(5), 517-519 (1997).
14. Meade BD, Lynn F, Reed GF et al. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics 96(3 Pt 2), 595-600 (1995).
15. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334(6), 341-348 (1996).
16. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334(6), 349-355 (1996).
17. Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am. J. Dis. Child 145(11), 1285-1289 (1991).
18. Olin P, Storsaeter J. Vaccine efficacy. In: A Clinical Trial of Acellular Pertussis Vaccines in Sweden (Technical Report). National Bacteriological Laboratory, Stockholm, Sweden, 1-28 (1988).
19. Trollfors B, Taranger J, Lagergård T et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333(16), 1045-1050 (1995).
20. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N. Engl. J. Med. 334(6), 391-392 (1996).
21. Olin B, Rasmussen F, Gottfarb P. Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. Int. J. Infect. Dis. 1(3), 143-147 (1997).
22. Simondon F, Preziosi MP, Yam A et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15(15), 1606-1612 (1997).
23. Hoppenbrouwers K, Kanra G, Roelants M et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 17(7-8), 875-886 (1999).
24. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350(9091), 1569-1577 (1997).
25. Pertussis. In: Immunisation Against Infectious Disease - The Green Book. Salisbury D, Ramsay M, Noakes K (Eds). Department of Health, UK, 277-293 (2006).
26. Poland GA. Still more questions on pertussis vaccines. Lancet 350(9091), 1564-1565 (1997).
27. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlson R-M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43(6), 2856-2865 (2005). • Recent demonstration of FIM2-FIM3 shifts related to DTPa5.
28. Stefanelli P, De Marzi L, Robino L et al. Characterization of Bordetella pertussis strains of recent isolation. New Microbiol. 22(3), 187-194 (1999).
29. van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol. Infect. 123(3), 403-411 (1999).
30. Englund JA, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J. Infect. Dis. 166(6), 1436-1441 (1992).
31. Tiru M, Askelöf P, Granström M, Hallander H. Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies. Dev. Biol. Stand. 89, 239-245 (1997).
32. Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to pertussis. Commun. Dis. Rep. CDR Rev. 2(13), R155-R156 (1992).
33. Stehr K, Cherry JD, Heininger U et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 101(1 Pt 1), 1-11 (1998).
34. Hoppe JE, Preston NW. Whooping cough in West Germany. Lancet 326(8458), 776 (1985).
35. Enders G, Rapp I, Biber M, Preston NW, Carter EJ. Whooping cough in Stuttgart. Lancet 331(8594), 1113 (1988).
36. Ramakrishnan S, Newland P, Xing DKL, Heininger U, Cherry JD, Corbel MJ. Serotypes of Bordetella pertussis isolates from German children participating in a pertussis vaccine efficacy trial and from non-study participants living in the same geographic area. 7th International Symposium on Pertussis: Genome, Pathogenesis, and Immunity. Cambridge, UK, 18-22 September, 2002.
37. Robinson A, Gorringe AR, Funnell SGP, Fernandez M. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7(4), 321-324 (1989).
38. Caro V, Elomaa A, Brun D, Mertsola J, He Q, Guiso N. Bordetella pertussis, Finland and France. Emerg. Infect. Dis. 12(6), 987-989 (2006).
39. Olin P, Gustafsson L, Barreto L et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21(17-18), 2015-2021 (2003).
40. Denoël P, Poolman J, Carletti G, Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine 20(19-20), 2551-2555 (2002).
41. Halperin SA, Barreto L, Eastwood BJ, Medd L, Guasparini R, Mills E. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine 15(3), 295-300 (1997).
42. Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin. Infect. Dis. 28(5), 995-1001 (1999).
43. Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. 185(10), 1448-1453 (2002).
44. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J. 22(1), 22-27 (2003).
45. Van Amersfoorth SCM, Schouls LM, van der Heide HGJ et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol. 43(6), 2837-2843 (2005). • Recent evaluation of B. pertussis polymorphism in different European countries.
46. Elomaa A, Advani A, Donnelly D et al. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J. Clin. Microbiol. 43(8), 3681-3687 (2005).
47. Tsang RSW, Lau AKH, Sill ML et al. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42(11), 5364-5367 (2004).
48. Kourova N, Caro V, Weber C et al. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J. Clin. Microbiol. 41(8), 3706-3711 (2003).
49. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 132(2), 185-193 (2004).
50. Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur. J. Clin. Microbiol. Infect. Dis. 19(2), 77-88 (2000).
51. van Loo IHM, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40(6), 1994-2001 (2002).
52. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HGJ, Gaastra W, Willems RJL. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66(2), 670-675 (1998).
53. Mooi FR, Hallander H, Wirsing von König CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 174-181 (2000).
54. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53(5), 355-365 (2004).
55. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69(9), 5520-5528 (2001).
56. Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert. Rev. Vaccines 4(5), 757-778 (2005).
57. Caro V, Njamkepo E, van Amersfoorth SCM et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microb. Infect. 7(7-8), 976-982 (2005).
58. Byrne S, Slack AT. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. BMC Infect. Dis. 6(1), 53 (2006).
59. de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MAE. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg. Infect. Dis. 6(4), 348-357 (2000).
60. Hausman SZ, Burns DL. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun. 68(6), 3763-3767 (2000).
61. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr. Infect. Dis. J. 22(11), 956-959 (2003).
62. Centers for Disease Control and Prevention. Pertussis - United States, 1997-2000. Morb. Mortal. Wkly Rep. 51(4), 73-76 (2002).
63. Forsyth KD, Campins-Marti M, Caro J et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin. Infect. Dis. 39(12), 1802-1809 (2004). • Recommendation of the introduction of booster immunization.
64. Lee GM, Lett S, Schauer S et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin. Infect. Dis. 39(11), 1572-1580 (2004).
65. Güris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. 28(6), 1230-1237 (1999).
66. Salmaso S, Mastrantonio P, Tozzi AE et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108(5), e81 (2001).
67. Lacombe K, Yam A, Simondon K, Pinchinat S, Simondon F. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine 23(5), 623-628 (2004).
68. Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(5), S58-S61 (2005).
69. Baughman AL, Bisgard KM, Edwards KM et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab. Immunol. 11(6), 1045-1053 (2004).
70. Pebody RG, Gay NJ, Giammanco A et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol. Infect. 133(1), 159-171 (2005).
71. Águas R, Gonçalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect. Dis. 6(2), 112-117 (2006).
72. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118(3), 978-984 (2006). • Recent data on duration of protection after introduction of DTPa immunization in Sweden.
73. Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 353(15), 1555-1563 (2005). • Demonstration of efficacy of Pa immunization in adolescents and adults.
74. Health council of The Netherlands. Vaccination against pertussis. The Hague: Health Council of The Netherlands publication no. 2004/04 (2004) www.gr.nl
75. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden - 7-year report, October 1997-September 2004 (2005) www.smittskyddsinstitutet.se/SMItemplates/Article_5894.aspx